Abstract
Via a dextran brige, adriamycin was conjugated to McAb Zh805. Under the experimental con-dition used, the rate of adriamycin conjugated to McAb Zh805 was 62% with a little loss of the drug activity. The conjugate retained 73% of the original antibody activity. The in vitro cytotoxic activity of the conjugate was assayed by the inhibition of 3H-thymidine incorporation. The results showed that Zh805DA conjugate inhibited 86% of 3H-thymidine incorporation on HL-60 cells after a 20-hour exposure to the conjugate at a concentration of 20μg/ml. In contrast to HL-60 cells, only 24% of 3H-thymidine incorporation in FO cells was inhibited. The specific cytotoxicities of Zh805DA conjugate to various fresh leukemic cells and leukemic cell lines were measured and compared with thal of equimolar amounts of free adriamycin and of untreated Zh805. The results showed that Zh805DA conjugaies exhibited significantly stronger cytotoxicity against the leukemic cells of AML, especially FAB Ml, M2, M3, and HL-60 ,K562 cells than against the leukemic cells of ALL and FO cells,while free adriamycin exhibited more or less the same cytotoxicity to various fresh leukemic cells and leukemic cell lines. Key words: McAb; adriamycis; leukemia; immune directed therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
